Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 630 across all filing types
Latest filing 2024-03-26 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
江苏浩欧博生物医药股份有限公司关于以集中竞价交易方式首次回购公司股份的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Jiangsu Haobo Biopharmaceutical Co., Ltd. regarding the company's first share repurchase through centralized bidding on the Shanghai Stock Exchange. It details the number of shares repurchased, prices, total funds used, and references the board meeting approving the repurchase plan. The content focuses on the company's share buyback activity, including regulatory compliance and future intentions for the repurchased shares. There are no financial statements or comprehensive financial data presented, nor is this a report or presentation. The document fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback of its own shares.
2024-03-26 Chinese
江苏浩欧博生物医药股份有限公司关于以集中竞价交易方式回购公司股份的回购报告书
Transaction in Own Shares Classification · 95% confidence The document is a detailed announcement regarding the company's plan to repurchase its own shares through centralized bidding on the stock exchange. It includes specifics about the purpose of the repurchase (employee stock ownership plan or equity incentives), the amount of funds allocated, the price limits, the timeline, the source of funds, and the impact on the company's financials and shareholding structure. It also discusses the authorization for the repurchase and risk factors associated with the repurchase. The document is not a financial report, earnings release, or management discussion, but a formal report on the share repurchase plan and its implementation. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company announcements about buying back or selling its own shares (share repurchase/issuance). The document length and content confirm it is the report itself, not just an announcement of a report publication or a regulatory filing. Therefore, the correct classification is POS with high confidence.
2024-03-21 Chinese
江苏浩欧博生物医药股份有限公司关于回购股份事项前十名股东和前十名无限售条件股东持股情况的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement from Jiangsu Haobo Biopharmaceutical Co., Ltd. regarding the top ten shareholders and top ten unrestricted shareholders as of a specific date (March 8, 2024). It references a board meeting resolution about share repurchase and provides detailed shareholding data. The document is not a financial report, earnings release, or management discussion. It is a disclosure related to shareholding structure in the context of a share repurchase plan. This fits the category of Transaction in Own Shares (POS), which covers announcements about share buybacks or related shareholder information. The document length is short (1711 characters), and it contains substantive data about shareholdings, not just a report publication announcement or certification. Therefore, the best classification is POS with high confidence.
2024-03-13 Chinese
江苏浩欧博生物医药股份有限公司关于实际控制人、董事长、总经理提议回购公司股份的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from the company Jiangsu Haobo Biopharmaceutical Co., Ltd. regarding a proposal by the actual controller, chairman, and general manager to repurchase company shares. It details the proposal's background, purpose, method, price limits, funding source, and related commitments. The text focuses on the share repurchase plan and does not contain financial statements or quarterly/yearly results. It is not a report but an announcement about a capital action (share repurchase). Therefore, the appropriate classification is 'Transaction in Own Shares' (POS). The document length is short (1670 characters), but it contains substantive information about the share repurchase proposal, not just a notice of report publication or regulatory filing. Hence, POS is the best fit with high confidence.
2024-03-10 Chinese
江苏浩欧博生物医药股份有限公司第三届董事会第九次会议决议公告
Transaction in Own Shares Classification · 100% confidence The document is a formal announcement of a board meeting resolution by Jiangsu Haoubo Biopharmaceutical Co., Ltd. It details the board's approval of a share repurchase plan, including specifics on the repurchase price, amount, and authorization to management. The document does not contain financial statements or detailed financial data but is an official disclosure of a board decision related to capital actions. It references another announcement (2024-007) for more details. Given the content focuses on a board resolution about share repurchase, this fits the category of Transaction in Own Shares (POS). The document length is short and it is not a report or financial statement itself, but an announcement of a board decision on share repurchase.
2024-03-10 Chinese
江苏浩欧博生物医药股份有限公司关于以集中竞价交易方式回购公司股份暨推动公司“提质增效重回报”行动方案的公告
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement from Jiangsu Haobo Biopharmaceutical Co., Ltd. regarding a share repurchase plan through centralized bidding transactions. It includes specifics about the purpose, amount, price, duration, and risks of the share buyback, as well as the impact on the company's financials and shareholder structure. The document is not a financial report, earnings release, or management discussion, but rather a formal disclosure about a capital action involving the company's own shares. This fits the definition of a Transaction in Own Shares (POS) filing, which covers share repurchase announcements and related details. The document length and content confirm it is the announcement itself, not a brief notice or a report publication announcement.
2024-03-10 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.